Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00249886|
Recruitment Status : Withdrawn
First Posted : November 7, 2005
Last Update Posted : September 19, 2006
The purpose of the study is to evaluate whether it is advantageous for adolescents who have recovered from depression after a 6 to 12 week course of antidepressant treatment to stay on the treatment a further 6 months or is it just as helpful to stop the medication after recovery.
The hypothesis is that adolescents with major depression who recover from the 6 to 12 week trial of citalopram will be less likely to have a recurrence of depression over a 6 month period if continued on the citalopram as compared to those who discontinue the medication.
|Condition or disease||Intervention/treatment||Phase|
|Major Depression||Drug: Citalopram||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||September 2002|
|Study Completion Date :||November 2006|
- Relapse - subject meets criteria for an episode of major depression for 2 weeks or more.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00249886
|Sunnybrook Health Sciences Centre|
|Toronto, Ontario, Canada, M4N 3M5|
|Principal Investigator:||Anthony J Levitt, MD||Sunnybrook Health Sciences Centre|